SIRT3 is a novel prognostic biomarker for esophageal squamous cell carcinoma

Medical Oncology

Volumn 31, Issue 8, 2014, Pages

  Yan, Shu Mei ^a   Han, Xian ^b   Han, Pei Jin ^b   Chen, He Mu ^c   Huang, Li Yun ^b   Li, Yong ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c NORTHEAST FORESTRY UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; Prognosis; SIRT3

Indexed keywords

SIRTUIN 3; SIRT3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UNIVARIATE ANALYSIS; VERY ELDERLY; CARCINOMA, SQUAMOUS CELL; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; SIRTUIN 3; TUMOR MARKERS, BIOLOGICAL;

EID: 84903810383     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0103-8     Document Type: Article

References (35)

1. Tong L, Yuan S, Feng F, Zhang H. Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study. Dis Esophagus. 2012;25(1):72-80. doi:10.1111/j.1442-2050.2011.01211.x.
2. Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer. 2003;105(1):98-100. doi:10.1002/ijc.11029. (Pubitemid 36418492)
3. Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248(4):549-56. doi:10.1097/SLA.0b013e318188c474.
4. Wijnhoven BP, Tran KT, Esterman A, Watson DI, Tilanus HW. An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg. 2007;245(5):717-25. doi:10.1097/01.sla.0000251703.35919.02. (Pubitemid 46684101)
5. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26(37):5489-504. doi:10.1038/sj.onc. 1210616. (Pubitemid 47255930)
6. Haigis MC, Guarente LP. Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006;20(21):2913-21. doi:10.1101/gad.1467506. (Pubitemid 44771725)
7. Bakin RE, Jung MO. Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis. J Biol Chem. 2004;279(49):51218-25. doi:10.1074/jbc.M409271200. (Pubitemid 40017865)
8. Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci. 2010;35(12):669-75. doi:10.1016/j.tibs.2010.07.003.
9. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27(24):8807-14. doi:10.1128/MCB.01636-07.
10. Guan KL, Xiong Y. Regulation of intermediary metabolism by protein acetylation. Trends Biochem Sci. 2011;36(2):108-16. doi:10.1016/j.tibs.2010.09. 003.
11. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009;324(5930):1076-80. doi:10.1126/science.1164097.
12. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, et al. Regulation of cellular metabolism by protein lysine acetylation. Science. 2010;327(5968):1000- 4. doi:10.1126/science.1179689.
13. Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ, et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer. 2011;117(8):1670-8. doi:10.1002/cncr.25676.
14. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer. 2006;95(8):1056-61. doi:10.1038/sj.bjc.6603384. (Pubitemid 44606833)
15. Wang JX, Yi Y, Li YW, Cai XY, He HW, Ni XC, et al. Downregulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. BMC Cancer. 2014;14(1):297. doi:10.1186/1471-2407-14-297.
16. Desouki MM, Doubinskaia I, Gius D, Abdulkadir SA. Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Hum Pathol. 2014;45(5):1071-7. doi:10.1016/j.humpath. 2014.01.004.
17. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2007;404(1):1-13. doi:10.1042/BJ20070140. (Pubitemid 46788079)
18. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359-407. doi:10.1146/annurev.genet.39.110304.095751. (Pubitemid 43011120)
19. Li S, Banck M, Mujtaba S, Zhou MM, Sugrue MM, Walsh MJ. p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PLoS One. 2010;5(5):e10486. doi:10.1371/journal.pone.0010486.
20. Kim SH, Lu HF, Alano CC. Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS One. 2011;6(3):e14731. doi:10.1371/journal.pone.0014731.
21. Marfe G, Tafani M, Indelicato M, Sinibaldi-Salimei P, Reali V, Pucci B, et al. Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J Cell Biochem. 2009;106(4):643-50. doi:10.1002/jcb.22044.
22. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17(1):41-52. doi:10.1016/j.ccr.2009.11.023.
23. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell. 2011;19(3):416-28. doi:10.1016/j.ccr.2011.02.014.
24. Bell EL, Emerling BM, Ricoult SJ, Guarente L. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene. 2011;30(26):2986-96. doi:10.1038/onc.2011.37.
25. Zhao Y, Yang H, Wang X, Zhang R, Wang C, Guo Z. Sirtuin-3 (SIRT3) expression is associated with overall survival in esophageal cancer. Ann Diagn Pathol. 2013;17(6):483-5. doi:10.1016/j.anndiagpath.2013.06.001.
26. Cimen H, Han MJ, Yang Y, Tong Q, Koc H, Koc EC. Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry. 2010;49(2):304-11. doi:10.1021/bi901627u.
27. Finley LW, Haas W, Desquiret-Dumas V, Wallace DC, Procaccio V, Gygi SP, et al. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. PLoS One. 2011;6(8):e23295. doi:10.1371/journal.pone.0023295.
28. Finley LW, Haigis MC. Metabolic regulation by SIRT3: implications for tumorigenesis. Trends Mol Med. 2012;18(9):516-23. doi:10.1016/j.molmed.2012.05. 004.
29. Li D, Ueta E, Kimura T, Yamamoto T, Osaki T. Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci. 2004;95(8):644-50. (Pubitemid 39255811)
30. Azad N, Iyer A, Vallyathan V, Wang L, Castranova V, Stehlik C, et al. Role of oxidative/nitrosative stress-mediated Bcl-2 regulation in apoptosis and malignant transformation. Ann NY Acad Sci. 2010;1203:1-6. doi:10.1111/j.1749- 6632.2010.05608.x.
31. Azad N, Iyer AK, Wang L, Lu Y, Medan D, Castranova V, et al. Nitric oxide-mediated bcl-2 stabilization potentiates malignant transformation of human lung epithelial cells. Am J Respir Cell Mol Biol. 2010;42(5):578-85. doi:10.1165/rcmb.2009-0094OC.
32. Grenman R, Burk D, Virolainen E, Wagner JG, Lichter AS. Carey TE radiosensitivity of head and neck cancer cells in vitro. A 96-well plate clonogenic cell assay for squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1988;114(4):427-31.
33. Carey TE, Van Dyke DL, Worsham MJ, Bradford CR, Babu VR, Schwartz DR, et al. Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UM-SCC-17A and UM-SCC-17B. Cancer Res. 1989;49(21):6098- 107. (Pubitemid 19274176)
34. Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta. 2011;1816(1):80-8. doi:10.1016/j.bbcan.2011.04.004.
35. Porcu M, Chiarugi A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci. 2005;26(2):94-103. doi:10.1016/j.tips.2004.12.009. (Pubitemid 40170172)